NEW YORK, April 21 - CytRx has signed a license agreement with the University of Massachusetts Medical School for its proprietary portfolio of applications for RNAi-based gene silencing technology in obesity, type 2 diabetes, and cancer.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.
Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.
In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.
Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.